Analysts: Pfizer Program Restart is Positive for Regeneron and 3 More Research Notes to Browse

Regeneron (NASDAQ:REGN): Pfizer (NYSE:PFE) is restarting its anti-NGF program following the Food and Drug Administration’s lifting of the partial clinical hold for all anti-NGFs, which RBC Capital says is a positive for Regeneron. The company owns the rights to REGN475, an antibody to NGF that was previously in Phase II trials. The firm believes that the re-investing in the NGF program is a positive for Regeneron and adds another potential blockbuster to the pipeline. The shares are Outperform rated.


GameStop (NYSE:GME): Oppenheimer expects GameStop to benefit in the coming years from the launch of new video game consoles from Sony and Microsoft, and the firm believes the market continues to underestimate the intermediate-term earnings power of GameStop. It keeps an Outperform rating on the shares.


Cummins (NYSE:CMI): William Blair believes that Cummins’s second-quarter earnings report is a positive catalyst for the company’s shares. The firm reiterates an Outperform rating on the stock.


Altera (NASDAQ:ALTR): Following Altera’s in-line second-quarter results, Argus notes that the company’s backlog is rising, and the firm expects the company to become the market leader in the 14 nm category. The firm believes that the stock is becoming increasingly attractive and keeps a Buy rating on the shares.


Don’t Miss: Profit May Have Quadrupled, but Pfizer Couldn’t Hide Steep Sales Drop.